<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37177801</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3468</ISSN><JournalIssue CitedMedium="Internet"><Volume>597</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>FEBS letters</Title><ISOAbbreviation>FEBS Lett</ISOAbbreviation></Journal><ArticleTitle>TDP-43 N-terminal domain dimerisation or spatial separation by RNA binding decreases its propensity to aggregate.</ArticleTitle><Pagination><StartPage>1667</StartPage><EndPage>1676</EndPage><MedlinePgn>1667-1676</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/1873-3468.14635</ELocationID><Abstract><AbstractText>Aggregation of the 43&#x2009;kDa TAR DNA-binding protein (TDP-43) is a pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RNA binding and TDP-43 N-terminal domain dimerisation has been suggested to ameliorate TDP-43 aggregation. However, the relationship between these factors and the solubility of TDP-43 is largely unknown. Therefore, we developed new oligonucleotides that can recruit two TDP-43 molecules and interfere with their intermolecular interactions via spatial separation. Using these oligonucleotides and TDP-43-preferable UG-repeats, we uncovered two distinct mechanisms for modulating TDP-43 solubility by RNA binding: One is N-terminal domain dimerisation, and the other is the spatial separation of two TDP-43 molecules. This study provides new molecular insights into the regulation of TDP-43 solubility.</AbstractText><CopyrightInformation>&#xa9; 2023 Federation of European Biochemical Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miura</LastName><ForeName>Motoki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakaue</LastName><ForeName>Fumika</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1364-8730</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuno</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morita</LastName><ForeName>Kento</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hara</LastName><ForeName>Rintaro Iwata</ForeName><Initials>RI</Initials><Identifier Source="ORCID">0000-0003-2399-3431</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NucleoTIDE and PepTIDE Drug Discovery Center, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Ren</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishida</LastName><ForeName>Yurika</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokogawa</LastName><ForeName>Mariko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osawa</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Keio University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokota</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6490-3263</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NucleoTIDE and PepTIDE Drug Discovery Center, Tokyo Medical and Dental University, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>FEBS Lett</MedlineTA><NlmUniqueID>0155157</NlmUniqueID><ISSNLinking>0014-5793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">N-terminal domain interaction</Keyword><Keyword MajorTopicYN="N">RNA binding</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">UG-repeats</Keyword><Keyword MajorTopicYN="N">aggregation</Keyword><Keyword MajorTopicYN="N">dimerisation</Keyword><Keyword MajorTopicYN="N">solubility</Keyword><Keyword MajorTopicYN="N">spatial organisation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>3</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37177801</ArticleId><ArticleId IdType="doi">10.1002/1873-3468.14635</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y et&#xa0;al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351, 602-611.</Citation></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM et&#xa0;al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133.</Citation></Reference><Reference><Citation>Guenther EL, Cao Q, Trinh H, Lu J, Sawaya MR, Cascio D, Boyer DR, Rodriguez JA, Hughes MP and Eisenberg DS (2018) Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat Struct Mol Biol 25, 463-471.</Citation></Reference><Reference><Citation>Gitler AD and Shorter J (2011) RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion 5, 179-187.</Citation></Reference><Reference><Citation>Grese ZR, Bastos AC, Mamede LD, French RL, Miller TM and Ayala YM (2021) Specific RNA interactions promote TDP-43 multivalent phase separation and&#xa0;maintain liquid properties. EMBO Rep 22, e53632.</Citation></Reference><Reference><Citation>Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ and Lee VMY (2009) Expression of TDP-43 C-terminal fragments in&#xa0;vitro recapitulates pathological features of&#xa0;TDP-43 Proteinopathies. J Biol Chem 284, 8516-8524.</Citation></Reference><Reference><Citation>Nonaka T, Kametani F, Arai T, Akiyama H and Hasegawa M (2009) Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet 18, 3353-3364.</Citation></Reference><Reference><Citation>Budini M, Buratti E, Stuani C, Guarnaccia C, Romano V, De Conti L and Baralle FE (2012) Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem 287, 7512-7525.</Citation></Reference><Reference><Citation>Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M and Ryskeldi-Falcon B (2022) Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601, 139-143.</Citation></Reference><Reference><Citation>Shimonaka S, Nonaka T, Suzuki G, Hisanaga S and Hasegawa M (2016) Templated aggregation of TAR DNA-binding protein of 43 kDa (TDP-43) by seeding with TDP-43 Peptide fibrils. J Biol Chem 291, 8896-8907.</Citation></Reference><Reference><Citation>Shenoy J, el Mammeri N, Dutour A, Berbon M, Saad A, Lends A, Morvan E, Gr&#xe9;lard A, Lecomte S, Kauffmann B et&#xa0;al. (2020) Structural dissection of amyloid aggregates of TDP-43 and its C-terminal fragments TDP-35 and TDP-16. FEBS J 287, 2449-2467.</Citation></Reference><Reference><Citation>Mompe&#xe1;n M, Romano V, Pantoja-Uceda D, Stuani C, Baralle FE, Buratti E and Laurents DV (2017) Point mutations in the N-terminal domain of transactive response DNA-binding protein 43 kDa (TDP-43) compromise its stability, dimerization, and functions. J Biol Chem 292, 11992-12006.</Citation></Reference><Reference><Citation>Qin H, Lim LZ, Wei Y and Song J (2014) TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc Natl Acad Sci USA 111, 18619-18624.</Citation></Reference><Reference><Citation>Chang CK, Wu TH, Wu CY, Chiang MH, Toh EKW, Hsu YC, Lin KF, Liao YH, Huang TH and Huang JJT (2012) The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun 425, 219-224.</Citation></Reference><Reference><Citation>Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, Laferriere F, Maniecka Z, Pl&#xfc;ckthun A, Mittl P et&#xa0;al. (2017) Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun 8, 45.</Citation></Reference><Reference><Citation>Jiang LL, Xue W, Hong JY, Zhang JT, Li MJ, Yu SN, He JH and Hu HY (2017) The N-terminal dimerization is required for TDP-43 splicing activity. Sci Rep 7, 6196.</Citation></Reference><Reference><Citation>Kuo PH, Chiang CH, Wang YT, Doudeva LG and Yuan HS (2014) The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res 42, 4712-4722.</Citation></Reference><Reference><Citation>Buratti E, D&#xf6;rk T, Zuccato E, Pagani F, Romano M and Baralle FE (2001) Nuclear factor TDP-43 and SR proteins promote in&#xa0;vitro and in&#xa0;vivo CFTR exon 9 skipping. EMBO J 20, 1774-1784.</Citation></Reference><Reference><Citation>Wang A, Conicella AE, Schmidt HB, Martin EW, Rhoads SN, Reeb AN, Nourse A, Ramirez Montero D, Ryan VH, Rohatgi R et&#xa0;al. (2018) A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase&#xa0;separation, and RNA splicing. EMBO J 37, e97452.</Citation></Reference><Reference><Citation>Lukavsky PJ, Daujotyte D, Tollervey JR, Ule J, Stuani C, Buratti E, Baralle FE, Damberger FF and Allain FHT (2013) Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat Struct Mol Biol 20, 1443-1449.</Citation></Reference><Reference><Citation>Sun Y, Arslan PE, Won A, Yip CM and Chakrabartty A (2014) Binding of TDP-43 to the 3'UTR of its cognate mRNA enhances its solubility. Biochemistry 53, 5885-5894.</Citation></Reference><Reference><Citation>Huang YC, Lin KF, He RY, Tu PH, Koubek J, Hsu YC and Huang JJ (2013) Inhibition of TDP-43 aggregation by nucleic acid binding. PLoS ONE 8, e64002.</Citation></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C et&#xa0;al. (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14, 459-468.</Citation></Reference><Reference><Citation>Ishiguro T, Sato N, Ueyama M, Fujikake N, Sellier C, Kanegami A, Tokuda E, Zamiri B, Gall-Duncan T, Mirceta M et&#xa0;al. (2017) Regulatory role of RNA chaperone TDP-43 for RNA Misfolding and repeat-associated translation in SCA31. Neuron 94, 108-124.e7.</Citation></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, Copley KE, Hurtle B, Portz B, Pyles NJ et&#xa0;al. (2019) RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron 102, 321-338.e8.</Citation></Reference><Reference><Citation>Rengifo-Gonzalez JC, el Hage K, Cl&#xe9;ment MJ, Steiner E, Joshi V, Craveur P, Durand D, Pastr&#xe9; D and Bouhss A (2021) The cooperative binding of TDP-43 to GU-rich RNA repeats antagonizes TDP-43 aggregation. Elife 10, e67605.</Citation></Reference><Reference><Citation>Obika S, Nanbu D, Hari Y, Andoh J, Morio K, Doi T and Imanishi T (1998) Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 20-O,40-C-methyleneribonucleosides. Tetrahedron Lett 39, 5401-5404.</Citation></Reference><Reference><Citation>Singh SK, Nielsen P, Koshkin AA and Wengel J (1998) LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chem Commun 1998, 455-456.</Citation></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J and Fawzi NL (2016) ALS mutations disrupt phase separation mediated by &#x3b1;-helical structure in the TDP-43 low-complexity C-terminal domain. Structure 24, 1537-1549.</Citation></Reference><Reference><Citation>Wang L, Kang J, Lim L, Wei Y and Song J (2018) TDP-43 NTD can be induced while CTD is significantly enhanced by ssDNA to undergo liquid-liquid phase separation. Biochem Biophys Res Commun 499, 189-195.</Citation></Reference><Reference><Citation>Conicella AE, Dignon GL, Zerze GH, Schmidt HB, D'Ordine AM, Kim YC, Rohatgi R, Ayala YM, Mittal J and Fawzi NL (2020) TDP-43 &#x3b1;-helical structure tunes liquid-liquid phase separation and function. Proc Natl Acad Sci USA 117, 5883-5894.</Citation></Reference><Reference><Citation>Zhang H, Elbaum-Garfinkle S, Langdon EM, Taylor N, Occhipinti P, Bridges AA, Brangwynne CP and Gladfelter AS (2015) RNA controls PolyQ protein phase transitions. Mol Cell 60, 220-230.</Citation></Reference><Reference><Citation>Che MX, Jiang LL, Li HY, Jiang YJ and Hu HY (2015) TDP-35 sequesters TDP-43 into cytoplasmic inclusions through binding with RNA. FEBS Lett 589, 1920-1928.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>